December 3, 2020
Business News

PhaseBio Provides Pemziviptadil (PB1046) Program Update

MALVERN, Pa. & SAN DIEGO–()–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that, after a strategic review of the VANGARD clinical trial that included an assessment of the evolving COVID-19 treatment landscape, feedback from the U.S. Food and Drug Administration (FDA) and an interim analysis of the VANGARD study data, it has elected to discontinue the trial. Importantly, pemziviptadil was generally well tolerated and there was no adverse safety signal reported in the VANGARD trial.

In response to the medical community’s rapidly evolving understanding of…

Click here to view the original article.

Related Posts

You might also like ...

Eastman Board Increases Dividend for 11th Consecutive Year
Mayville Engineering Company, Inc. Announces Appointment of Jennifer Kent to Board of Directors
Korea Fund Announces Adoption of Conditional Tender Offer Policy